Embody vs MEDVi: Which GLP-1 Provider Is Better?
By Iacob Pastina, Independent Researcher
MEDVi beats Embody overall, scoring 7.7/10 vs 7.3/10. Choose Embody for users looking for the lowest entry price with round-the-cloc. Choose MEDVi for users who want a low entry price with oral and injectable co.
A side-by-side comparison of Embody and MEDVi covering pricing, scores, medication types, insurance, and more to help you decide.
Embody
#31 of 40Compounded GLP-1 provider with 24/7 specialist support and competitive pricing for budget-conscious users.
Visit EmbodyMEDVi
#21 of 40Compounded GLP-1 platform offering both oral and injectable options with flexible dosing and affordable pricing.
Visit MEDVi| Feature | Embody | MEDVi |
|---|---|---|
| Our Score | 7.3/10 | 7.7/10 |
| Starting Price | $299/mo | $299/mo |
| Medication Type | Compounded | Compounded |
| Insurance Accepted | No | No |
| Best For | Users looking for the lowest entry price with round-the-clock specialist support | Users who want a low entry price with oral and injectable compounded options |
| Ranking | #31 | #21 |
Pros & Cons Compared
Embody
Pros
- +$149 first month is one of the lowest entry prices in the GLP-1 market — includes medication, metabolic report, and 1:1 guidance
- +Oral tirzepatide gum format available — one of the few platforms offering a non-injectable tirzepatide option for needle-phobic patients
- +24/7 specialist support included at no extra cost for questions about dosing, side effects, and progress
- +Personalized metabolic report helps you understand your body's baseline before starting treatment
Cons
- −Monthly refill price jumps to $299/mo after the first month — nearly double what competitors like Mochi ($99/mo + membership) or TrimRx ($179/mo) charge
- −Compounded medications only — no brand-name Wegovy or Zepbound available through the platform
- −Limited company transparency — founding date, headquarters, and pharmacy partners are not publicly disclosed
MEDVi
Pros
- +One of the few compounded providers offering both oral tablets and injectable semaglutide
- +Micro-dosing options available — can start at sub-standard doses for patients concerned about side effects
- +Sleek onboarding experience with clear progress tracking through their patient portal
- +$179/mo is competitive for a platform with both oral and injectable compounded formulations
Cons
- −Compounded medications only — no path to brand-name Wegovy or Zepbound through their platform
- −No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms
Our Verdict
MEDVi edges out Embody with a score of 7.7/10 vs 7.3/10. Choose Embody if you want: users looking for the lowest entry price with round-the-clock specialist support. Choose MEDVi if you want: users who want a low entry price with oral and injectable compounded options.